A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
Recap by typeshit. Post by Facebook on Facebook.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Obesity specialist Beverly Tchang posts her top three takeaways on the science of amylin based drugs after speaking at an AAFP event.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
A short link post on what patients should keep in mind as options for semaglutide and tirzepatide keep shifting. Details are at the source.
Loading…